摘要
目的开发样品制备批量易于放大的艾塞那肽长效微球制备工艺,及快速评价微球体外释放性质的方法。方法以高剪切乳化结合高压均质法制备初乳,并采用复凝聚法制备微球。工艺中初乳与凝聚液混合的步骤采用易工艺放大的静态混合法。采用将体外释放温度由37℃提高至45℃来加速评价微球中药物释放速度。结果采用高压均质法可将初乳粒径控制在约200 nm以下,形成的微球中药物包封率大于96.8%,1 h药物突释量小于0.5%。当制备微球的批量放大5倍时,所得微球的性质与小批量样品一致。体外释放研究显示,在37℃条件下,经过约17 d的延滞期后,药物可持续释放近4周。在45℃加速条件下,药物释放速度是37℃下的2.5倍,且释放曲线与37℃下基本一致,可通过加速条件快速评价微球的体外释放情况。结论以静态混合器对初乳和凝聚液进行混合来制备艾塞那肽长效微球,样品制备批量易于放大,易于实现产业化。通过加速条件可快速评价微球的体外释放性质。
OBJECTIVE To develop an easy to scale-up preparation process for exenatide-loaded long-acting microspheres, and develop a method that can be used to rapidly evaluate the in vitro release properties of the microspheres. METHODS The primary emulsion could be made by high shear emulsification process combined with high pressure homogenization method , then exenatide-loaded microspheres were prepared by a modified coacervation method. In the coacervation step, static mixer was used for mixing the primary emulsion and the coacervation reagent. RESULTS High pressure homogenization could reduce the size of the primary emulsion to about 200 nm. The encapsulation efficiency of microspheres was greater than 96. 8%, and the amount of burst release in 1 h was less than 0. 5%. When the scale of microspheres preparation was magnified by five times, the characteristics of the obtained microspheres was the same as the small scale batch. The in vitro release curves showed that the continued release time lasted for nearly 4 weeks after the 17 d lag phase. The drug release rate at 45 ~C was as high as 2. 5 times of that at 37 ℃, with same release curves. CONCLU- SION The established preparation process of exenatide-loaded long-acting microspheres, which uses static mixer for mixing the primary emulsion and coacervation reagent, is easy for scaling-up and industrialization. Accelerated test at 45 ℃ can be used to rapidly evaluate the in vitro release profile of the microspheres.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2016年第3期218-223,共6页
Chinese Pharmaceutical Journal
